136 related articles for article (PubMed ID: 8677431)
1. A cautionary tale.
Zinberg DS
Science; 1996 Jul; 273(5274):411. PubMed ID: 8677431
[No Abstract] [Full Text] [Related]
2. Thyroid storm.
Rennie D
JAMA; 1997 Apr; 277(15):1238-43. PubMed ID: 9103350
[No Abstract] [Full Text] [Related]
3. Research suppressed for seven years by drug company.
Wise J
BMJ; 1997 Apr; 314(7088):1145. PubMed ID: 9146378
[No Abstract] [Full Text] [Related]
4. Morality play.
Benet LZ
Science; 1996 Sep; 273(5283):1782; author reply 1784-5. PubMed ID: 8815536
[No Abstract] [Full Text] [Related]
5. Bioequivalence of levothyroxine preparations: industry sponsorship and academic freedom.
Eckert CH
JAMA; 1997 Apr; 277(15):1200-1. PubMed ID: 9103338
[No Abstract] [Full Text] [Related]
6. Sponsors lose fight to stop thyroxine study publication.
McCarthy M
Lancet; 1997 Apr; 349(9059):1149. PubMed ID: 11654726
[No Abstract] [Full Text] [Related]
7. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
DeGroot LJ
JAMA; 1997 Sep; 278(11):895; author reply 898-9. PubMed ID: 9302231
[No Abstract] [Full Text] [Related]
8. A duty to publish.
Nat Med; 1998 Oct; 4(10):1089. PubMed ID: 9771720
[No Abstract] [Full Text] [Related]
9. Publishing sensitive data: who calls the shots? Long-suppressed study finally sees light of day.
Vogel G
Science; 1997 Apr; 276(5312):525-6. PubMed ID: 9148408
[No Abstract] [Full Text] [Related]
10. Morality play.
Eckert C
Science; 1996 Sep; 273(5283):1784; author reply 1784-5. PubMed ID: 8815539
[No Abstract] [Full Text] [Related]
11. Release of study ends drug fracas.
Sternberg S
Sci News; 1997 Apr; 151(16):236. PubMed ID: 11655105
[No Abstract] [Full Text] [Related]
12. Drug company 'suppressed' publication of research.
Wadman M
Nature; 1996 May; 381(6577):4. PubMed ID: 8609985
[No Abstract] [Full Text] [Related]
13. Drug firm, relenting, allows unflattering study to appear.
Altman LK
N Y Times Web; 1997 Apr; ():A1, A16. PubMed ID: 11647207
[No Abstract] [Full Text] [Related]
14. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
Dreyer NA
JAMA; 1997 Sep; 278(11):897; author reply 898-9. PubMed ID: 9302237
[No Abstract] [Full Text] [Related]
15. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
Bell BM
JAMA; 1997 Sep; 278(11):896; author reply 898-9. PubMed ID: 9302234
[No Abstract] [Full Text] [Related]
16. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
Brantigan CO
JAMA; 1997 Sep; 278(11):897; author reply 898-9. PubMed ID: 9302236
[No Abstract] [Full Text] [Related]
17. Need a reagent? Just sign here..
Marshall E
Science; 1997 Oct; 278(5336):212-3. PubMed ID: 9340765
[No Abstract] [Full Text] [Related]
18. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
Birnbaum R
JAMA; 1997 Sep; 278(11):897-8; author reply 898-900. PubMed ID: 9302239
[No Abstract] [Full Text] [Related]
19. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
Lankin KM
JAMA; 1997 Sep; 278(11):897; author reply 898-900. PubMed ID: 9302238
[No Abstract] [Full Text] [Related]
20. Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising.
Donohoe M
JAMA; 1997 Sep; 278(11):896-7; author reply 898-9. PubMed ID: 9302235
[No Abstract] [Full Text] [Related]
[Next] [New Search]
